Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366418> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313366418 endingPage "68.5" @default.
- W4313366418 startingPage "68.5" @default.
- W4313366418 abstract "Abstract In Type 1 Diabetes (T1D) patients and non-obese diabetic (NOD) mice, autoreactive CD4 T cells contribute to destruction of insulin-producing β-cells in the pancreatic islets. Our lab has discovered that in NOD mice the endogenous ligand for the diabetogenic CD4 T cell clone BDC-2.5 is a hybrid insulin peptide (2.5HIP), consisting of a fragment from proinsulin fused to a peptide from chromogranin A (ChgA). The purpose of this study was to determine if tolerogenic poly(lactide-co-glycolide) (PLG) nanoparticles (NPs) coupled with 2.5HIP (2.5HIP-PLG) could be used to induce antigen-specific T cell tolerance. We have found that treatment with 2.5HIP-PLG NPs synergizes with a short course of low-dose recombinant IL-2, leading to robust induction of 2.5HIP-specific Foxp3+ regulatory T cells (Tregs) and prevention of spontaneous diabetes in 50% of NOD mice. In a disease reversal model, spontaneously diabetic NOD mice were transplanted with 500 syngeneic islets and recipients were infused with HEL-PLG (control) or 2.5HIP-PLG NPs pre- and post-transplant. In contrast to HEL-PLG treated mice that showed aggressive disease recurrence in around 2 weeks, graft destruction in 2.5HIP-PLG treated mice was significantly delayed up to an average of 8 weeks, indicating that targeting graft-infiltrating 2.5HIP-specific T cells dampens ongoing autoimmunity. Our current goal is to determine whether the therapeutic effects observed in the transplantation model are due to expansion of antigen-specific Tregs, induction of anergy in effector T cells, or both. This novel antigen-specific therapy using a disease-relevant neoantigen may have implications for development of an immune-modifying treatment for T1D patients." @default.
- W4313366418 created "2023-01-06" @default.
- W4313366418 creator A5001121007 @default.
- W4313366418 creator A5018120698 @default.
- W4313366418 creator A5033876610 @default.
- W4313366418 creator A5037436028 @default.
- W4313366418 creator A5038140076 @default.
- W4313366418 creator A5048730111 @default.
- W4313366418 creator A5073869003 @default.
- W4313366418 creator A5089837132 @default.
- W4313366418 date "2019-05-01" @default.
- W4313366418 modified "2023-09-26" @default.
- W4313366418 title "Development of a Novel Antigen-Specific Therapy for Autoimmune Diabetes Using an Insulin-ChgA Hybrid Peptide Neoantigen" @default.
- W4313366418 doi "https://doi.org/10.4049/jimmunol.202.supp.68.5" @default.
- W4313366418 hasPublicationYear "2019" @default.
- W4313366418 type Work @default.
- W4313366418 citedByCount "0" @default.
- W4313366418 crossrefType "journal-article" @default.
- W4313366418 hasAuthorship W4313366418A5001121007 @default.
- W4313366418 hasAuthorship W4313366418A5018120698 @default.
- W4313366418 hasAuthorship W4313366418A5033876610 @default.
- W4313366418 hasAuthorship W4313366418A5037436028 @default.
- W4313366418 hasAuthorship W4313366418A5038140076 @default.
- W4313366418 hasAuthorship W4313366418A5048730111 @default.
- W4313366418 hasAuthorship W4313366418A5073869003 @default.
- W4313366418 hasAuthorship W4313366418A5089837132 @default.
- W4313366418 hasConcept C126322002 @default.
- W4313366418 hasConcept C134018914 @default.
- W4313366418 hasConcept C147483822 @default.
- W4313366418 hasConcept C203014093 @default.
- W4313366418 hasConcept C2776090121 @default.
- W4313366418 hasConcept C2778013207 @default.
- W4313366418 hasConcept C2779306644 @default.
- W4313366418 hasConcept C2779727006 @default.
- W4313366418 hasConcept C2780130043 @default.
- W4313366418 hasConcept C2911091166 @default.
- W4313366418 hasConcept C555293320 @default.
- W4313366418 hasConcept C55851684 @default.
- W4313366418 hasConcept C71924100 @default.
- W4313366418 hasConcept C8891405 @default.
- W4313366418 hasConcept C90061646 @default.
- W4313366418 hasConceptScore W4313366418C126322002 @default.
- W4313366418 hasConceptScore W4313366418C134018914 @default.
- W4313366418 hasConceptScore W4313366418C147483822 @default.
- W4313366418 hasConceptScore W4313366418C203014093 @default.
- W4313366418 hasConceptScore W4313366418C2776090121 @default.
- W4313366418 hasConceptScore W4313366418C2778013207 @default.
- W4313366418 hasConceptScore W4313366418C2779306644 @default.
- W4313366418 hasConceptScore W4313366418C2779727006 @default.
- W4313366418 hasConceptScore W4313366418C2780130043 @default.
- W4313366418 hasConceptScore W4313366418C2911091166 @default.
- W4313366418 hasConceptScore W4313366418C555293320 @default.
- W4313366418 hasConceptScore W4313366418C55851684 @default.
- W4313366418 hasConceptScore W4313366418C71924100 @default.
- W4313366418 hasConceptScore W4313366418C8891405 @default.
- W4313366418 hasConceptScore W4313366418C90061646 @default.
- W4313366418 hasIssue "1_Supplement" @default.
- W4313366418 hasLocation W43133664181 @default.
- W4313366418 hasOpenAccess W4313366418 @default.
- W4313366418 hasPrimaryLocation W43133664181 @default.
- W4313366418 hasRelatedWork W1591511991 @default.
- W4313366418 hasRelatedWork W2029605369 @default.
- W4313366418 hasRelatedWork W2064751303 @default.
- W4313366418 hasRelatedWork W2068300193 @default.
- W4313366418 hasRelatedWork W2068435854 @default.
- W4313366418 hasRelatedWork W2151178653 @default.
- W4313366418 hasRelatedWork W2213860064 @default.
- W4313366418 hasRelatedWork W4285095339 @default.
- W4313366418 hasRelatedWork W4313366418 @default.
- W4313366418 hasRelatedWork W4313382087 @default.
- W4313366418 hasVolume "202" @default.
- W4313366418 isParatext "false" @default.
- W4313366418 isRetracted "false" @default.
- W4313366418 workType "article" @default.